跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DN-9
首页
药物
DN-9
DN-9
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Stapled peptide analogue of opioid/neuropeptide FF receptor multi-target molecule DN-9 as well as preparation and application of stapled peptide analogue
申请人: UNIV LANZHOU
优先权: 2023
CN
INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS
申请人: UNIV AARHUS
优先权: 2015
EP
Opioid/neuropeptide FF receptor multi-target cyclopeptide molecule as well as preparation and application thereof
申请人: SHANGHAI TIANCI LIFE SCIENCE DEV CO LTD
优先权: 2021
CN
Injectable and recoverable Fmoc-F/ALG hybrid dual-network gel and preparation method thereof
申请人: UNIV XI AN JIAOTONG
优先权: 2022
CN
Double-target peptide molecule targeting peripheral Kappa and Mu opioid receptors as well as preparation and application of double-target peptide molecule
申请人: UNIV LANZHOU
优先权: 2025
CN
Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof
申请人: SHANGHAI PUDONG NEW AREA PEOPLES HOSPITAL
优先权: 2020
CN
药物
反馈